Palliative Re-irradiation for Progressive Diffuse Intrinsic Pontine Glioma (DIPG) in Children

Hadassah Medical Center

Status and phase

Completed

Phase 2

Phase 1

Conditions

Pediatric Malignant Brain Tumor -Diffuse Intrinsic Pontine Glioma

Treatments

Radiation: Palliative re-irradiation for progressive DIPG in children

Study type

Interventional

Funder types

Other

Identifiers

NCT01777633

027812-HMO-CTIL

Details and patient eligibility

About

Although DIPG is not curable, re-irradiation with a modest total dose and short treatment time provides good palliation of symptoms, improves quality of life, delays disease progression and has minimal and manageable toxicity.

Treatment plan:

At progression, full radiological and clinical documentation necessary including a neurological exam by a neurologist will be done. Progressive patients will be referred to radiotherapy.

Radiation guidelines:

30.6 Gray (Gy) will be applied in 1.8 to 2Gy fractions in conformal radiation to tumor bed. Radiation will be done in standard accelerators and according to standard guidelines used in treatment for all brain tumor patients.

Enrollment

15 estimated patients

Sex

All

Ages

1 to 22 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age:1 year-22 years
Patient/parent consent
Diagnosis of DIPG based on short classic history, clinical signs (long tract signs, cranial nerve deficits and ataxia) and classic MRI features (more than 2/3 of the tumor is located within the pons and tumor encompasses more than 60% of the pons)
A patient will be eligible for reirradiation if progression is diagnosed following a period of at least 4 months of stable disease after first irradiation.
Progression may be either clinical (new neurological deficit or worsening of an old deficit in two separate physical examinations) or radiological (tumor growth of >25%)

Exclusion criteria